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Iron accumulation and associated oxidative stress in the brain have been consistently found
in several neurodegenerative diseases. Multiple genetic studies have been undertaken
to try to identify a cause of neurodegenerative diseases but direct connections have
been rare. In the iron ﬁeld, variants in the HFE gene that give rise to a protein involved
in cellular iron regulation, are associated with iron accumulation in multiple organs
including the brain. There is also substantial epidemiological, genetic, and molecular
evidence of disruption of cholesterol homeostasis in several neurodegenerative diseases,
in particular Alzheimer’s disease (AD). Despite the efforts that have been made to
identify factors that can trigger the pathological events associated with neurodegenerative
diseases they remain mostly unknown. Because molecular phenotypes such as oxidative
stress, synaptic failure, neuronal loss, and cognitive decline, characteristics associated
with AD, have been shown to result from disruption of a number of pathways, one
can easily argue that the phenotype seen may not arise from a linear sequence of
events. Therefore, a multi-targeted approach is needed to understand a complex disorder
like AD. This can be achieved only when knowledge about interactions between the
different pathways and the potential inﬂuence of environmental factors on them becomes
available. Toward this end, this review discusses what is known about the roles and
interactions of iron and cholesterol in neurodegenerative diseases. It highlights the effects
of gene variants of HFE (H63D- and C282Y-HFE) on iron and cholesterol metabolism and
how they may contribute to understanding the etiology of complex neurodegenerative
diseases.
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INTRODUCTION
The average increase in life expectancy has been accompanied
by an increase in the number of people with dementia, a prob-
lem expected to affect half of those living to be 85 or older. The
most prevalent form of dementia is Alzheimer’s disease (AD) and
its incidence is expected to triple by 2050 (Hebert et al., 2013).
The observations that more than 40% of AD patients carried
the ApoE4 allele (Cedazo-Minguez and Cowburn, 2001) and that
those carrying both the ApoE4 allele and expressing the H63D
variant of the hemochromatosis protein HFE were prone to ear-
lier onset of AD (Moalem et al., 2000; Percy et al., 2008) support
the hypothesis that disruption of the normal metabolism of both
iron and cholesterol contribute to AD. More speciﬁcally, the need
for a discussion of the role of iron and cholesterol in neurode-
generative disease stems from our observation that disruption of
normal iron metabolism in H63D-HFE-expressing human neu-
roblastoma cells resulted in altered cholesterol metabolism as well
as our ﬁndings that mice expressing the orthologous H67D-HFE
had alterations in brain iron and cholesterol metabolism and a
reduction in brain volume that correlated with poorer recognition
and spatial memory, symptoms associated with AD (Ali-Rahmani
et al., 2014a).
IRON IN NEURODEGENERATIVE DISEASES
Numerous studies have implicated metals such as iron, copper,
zinc, and aluminum in the pathogenesis of AD (Sayre et al., 2000;
Connor et al., 2001; Bush, 2003; Maynard et al., 2005; Connor and
Lee, 2006; Liu et al., 2006; Roberts et al., 2012). Evidence indicates
that oxidative stress induced by excess iron contributes to neu-
rodegeneration (Castellani et al., 2007). Because iron is the most
abundant transition metal in the body and is readily available
from several dietary options, it is important to understand how
its regulation in the body is inﬂuenced by other factors and how
its elevation or depletion affects cellular processes that could lead
to AD pathogenesis. To understand the role of iron in neurode-
generation, it is necessary to understand its normal function and
regulation.
ROLE OF IRON IN BRAIN
Iron is essential for a number of cellular processes needed for
survival. It is a required cofactor for a number of enzymes
involved in cell functions such as energy production (mito-
chondrial electron transport chain), DNA synthesis and repair,
ribosome biogenesis, neurotransmitter synthesis, myelin synthe-
sis and lipid metabolism, and cell cycle regulation. Iron is also
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needed for heme production and formation of iron-sulfur clusters
that are essential for electron transport and DNA repair (Rouault
and Tong, 2005; Tong and Rouault, 2006). Though these reactions
occur in every organ, the role of iron in the brain is particularly
important. Brain has the highest demand for oxygen of all organs
and iron-containing neuroglobin is essential to meet this need. In
addition, tomaintain the complex communication network and to
establish plasticity, the brain constantly remodels cell contacts and
synapses. These processes rely on protein synthesis by ribosomes
which, in turn, depend on [4Fe–4S] cluster-containing proteins
(Kispal et al., 2005). The iron-sulfur clusters are also essential for
DNA synthesis (Netz et al., 2012). Moreover, iron is an essen-
tial trophic factor needed for myelination. This is because key
enzymes such as 3-hydroxy-3-methylglutaryl-coenzyme A reduc-
tase (HMGCoAR), squalene synthase, and glucose-6-phosphate
dehydrogenase needed for the biosynthesis of myelin cholesterol
and lipids require iron as a cofactor (Lange and Que, 1998;
Todorich and Connor, 2004). The role of iron in these processes
is thought to reﬂect its ability to (1) donate electrons needed for
redox reactions, (2) transfer electrons in mitochondria, and (3) to
bind oxygen in heme. But if iron accumulates in an unchelated
form, its ability to readily exchange electrons can result in forma-
tion of reactive free radicals by the Fenton reaction (Lloyd et al.,
1997). In turn, this can lead to oxidative stress that can negatively
impact a number of cellular processes and disrupt cell membrane
integrity. Because oxidative stress is considered a causative agent
in the etiology of AD (Castellani et al., 2007; Cai et al., 2011), the
role of iron and disorders resulting in iron overload have been
under intense investigation for their potential role as a risk factor
for AD.
IRON IN AD
Several studies have reported that brain iron content and expres-
sion of iron-regulating proteins such as ferritin (Frt; high expres-
sion indicates more iron) increase with age, but the increase in
iron is greater than ferritin thus suggesting the increased iron is
not stored properly (Hallgren and Sourander, 1958; Milton et al.,
1991; Connor et al., 1992a,b, 1995; Bartzokis et al., 1994, 2007;
Martin et al., 1998; Hirose et al., 2003). The ﬁnding that iron accu-
mulation is signiﬁcantly higher in brains of patients with AD or
mild cognitive impairment (MCI) than in those of age-matched
non-demented controls (Ding et al., 2009) supports the proposal
that the increase in iron underlies age-related cognitive decline
(Bartzokis, 2009). Disturbances in iron metabolism have been
found in post-mortem brain tissue from patients with AD, in
cerebrospinal ﬂuid (CSF) and in vivo using magnetic resonance
imaging (MRI). Regions where iron deposition was found include
the hippocampus, basal ganglia and cortex (Loefﬂer et al., 1995;
Bartzokis et al., 2000; Ding et al., 2009) as well as senile plaques
and neuroﬁbrillary tangles and cells surrounding them (Con-
nor et al., 1992a). Moreover, higher brain iron content was also
found to correlate with the severity of cognitive impairment (Zhu
et al., 2009). Thus, use of MRI to monitor brain iron has been
proposed as a method for assessing disease progression. Excess
unchelated iron is considered a major cause of oxidative stress
that can lead to modiﬁcation of proteins, lipids, DNA, and RNA,
thereby, inducing several features associatedwithAD(Markesbery,
1997; Ferrari, 2000). These alterations are toxic to cells because
they result in activation of cell apoptosis pathways and eventually
cell death. In fact, markers of protein oxidation and lipid perox-
idation were consistently found to be elevated in the brains and
CSF samples from AD patients and those with MCI who subse-
quently developedAD (Markesbery, 1997; Pratico et al., 2002; Brys
et al., 2009). Moreover, markers of lipid peroxidation in ventricu-
lar ﬂuid were reported to correlate with cortical atrophy, reduced
brain weight and severity of AD (Montine et al., 1999). Proteins
involved in maintaining iron homeostasis include the transferrin
receptor (TfR; iron uptake), transferrin (Tf; iron transport), fer-
ritin (Frt; iron storage), HFE (iron uptake), ceruloplasmin (iron
transport; feroxidase- conversion of Fe2+ to Fe3+), DMT1 (iron
export), and ferroportin (iron export). Indeed, alterations in the
expression pattern of Tf, Frt, and HFE were found in brains of AD
patients and are discussed below. Moreover, genetic mutations
in Tf (C2 variant; rs1049296) and two variants of HFE, C282Y
(rs1800562) and H63D (rs1799945), were shown to affect body
iron status (Fleming et al., 2000; Bartzokis et al., 2010; Kauwe et al.,
2010), and oxidative stress (Loefﬂer et al., 1995; Lleo et al., 2002).
WhereH63Dhas been associatedwith increased risk of AD,C282Y
has been found to be protective for AD. There is substantial evi-
dence for the role of iron overload in AD that is further supported
by epidemiological evidence implicating variants of iron manage-
ment proteins in AD risk. The AlzGene meta-analysis of the Tf C2
allele (Bertram et al., 2007; www.alzgene.org/) currently shows a
signiﬁcant, although low, odds ratio of AD: 1.2 (95% conﬁdence
interval, 1.06–1.3; June 2010), with a similar pattern in Caucasians
and east Asians.
IRON, HFE, AND AD
Iron accumulation in the brain is accompanied by an increase
in oxidative stress that is consistently observed in AD (Connor
et al., 1992a; Markesbery, 1997; Liu et al., 2005; Maynard et al.,
2005). The high iron (HFE) gene product primarily regulates
iron uptake into cells by interacting with the TfR to restrict
Tf binding (Feder et al., 1998). Genetic variants of the HFE
gene are unable to maintain iron homeostasis, and in particu-
lar, the H63D variant has been under investigation as a potential
risk factor for neurodegenerative diseases. Several studies have
reported an increased frequency of the H63D mutation in AD
patients (Moalem et al., 2000; Sampietro et al., 2001; Combarros
et al., 2003; Pulliam et al., 2003; Connor and Lee, 2006). Pul-
liam et al. (2003) found increased levels of markers of oxidative
stress in individuals with HFE mutations compared to controls.
The H63D mutation was expressed ∼5 times more frequently in
AD patients younger than 70 years compared to patients over 80
(Sampietro et al., 2001). Indeed, MRI studies revealed increased
accumulation of iron in carriers of HFE mutations (Nielsen et al.,
1995; Berg et al., 2000). Studies have shown that iron staining
is most dense in the proximity of amyloid beta (Aβ) plaques
and in cells associated with plaques (Connor et al., 1992b) and
that iron promotes deposition of Aβ (Rottkamp et al., 2001).
Interestingly, a similar pattern was observed with respect to
HFE expression in AD brains, suggesting HFE expression may
be increased in cells in the vicinity of the plaque. A normal
response of HFE is to limit iron uptake thus these cells may
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be trying to limit iron uptake; a function that would be com-
promised if the mutant protein is expressed (Connor and Lee,
2006).
HFE GENE AND VARIANTS
HFE (high iron), originally called HLA-H, is a major histocompat-
ibility complex (MHC) class I-like gene. It is located on the short
arm of chromosome 6 and was ﬁrst identiﬁed by Simon et al.
(1976) in association with an iron overload disorder called hered-
itary hemochromatosis (HH). The HFE gene encodes a 49 kDa
membrane glycoprotein that resembles the MHC-class1 family
of proteins. The three most common single nucleotide polymor-
phisms (SNPs) in the HFE gene are H63D (rs1799945 in exon 2),
C282Y (rs1800562 in exon 4), and S65C (Merryweather-Clarke
et al., 2000; Le Gac et al., 2001). Examination of the frequency and
global distribution of HFE mutations indicated that HFE variants
aremost common inCaucasianpopulationswith a frequencyof up
to 25% for H63D, 12% for C282Y, and 1.6–5.5% for S65C. S65C
is not as common as the other two variants (Camaschella et al.,
2002) and has not been associated with physiological changes or
diseases (Le Gac et al., 2001).
Not only are the H63D and C282Y variants prevalent, epidemi-
ological evidence associates them with several neurodegenerative,
metabolic diseases, andmalignancies. ThoughC282Y is less preva-
lent in the general population than H63D, it is strongly associated
with HH and recently was identiﬁed as a risk factor for prostate,
breast, colorectal, and brain tumors (Shaheen et al., 2003; Syr-
jakoski et al., 2006; Osborne et al., 2010; Gannon et al., 2011). It
has also been found to protect against neurodegenerative diseases
(Buchanan et al., 2002; Correia et al., 2009). In contrast, the H63D
variant was identiﬁed as a risk factor for several diseases such as
AD (Moalem et al., 2000; Sampietro et al., 2001; Combarros et al.,
2003; Pulliam et al., 2003; Percy et al., 2008), amyotrophic lateral
sclerosis (ALS; Wang et al., 2004; Goodall et al., 2005), and stroke
(Ellervik et al., 2007).
FUNCTION OF HFE
The best characterized function of HFE is its role in regulation of
cellular iron uptake which it mediates by binding to the TfR. Bind-
ing afﬁnity of HFE for TfR is comparable to the binding afﬁnity of
iron-loaded transferrin (holotransferrin; Feder et al., 1998). When
a cell has enough iron, the HFE competitively binds to the TfR at
the same site as iron-loaded Tf molecules thereby preventing iron
uptake via endocytosis. Formation of the HFE-TfR complex is
pH-dependent, with a neutral pH allowing tight binding and an
acidic pH inhibiting it (Lebron et al., 1998, 1999). HFE can pre-
vent endocytosis of TfR alone by inducing its phosphorylation.
This results in higher expression of cell surface TfR than is found
intracellularly (Salter-Cid et al., 2000).
The function of HFE in iron regulation is disrupted by muta-
tions causing formation of the H63D- and C282Y-HFE variants.
It has been shown that while WT-HFE bound to TfR allows only
one iron bound Tf (Fe-Tf) to bind per TfR and be taken up by
cells (Lebron et al., 1998, 1999), H63D-HFE allows uptake of more
than one molecule of Fe-Tf because it does not reduce the afﬁnity
of Fe-Tf for TfR. Because C282Y-HFE is retained in the trans-golgi
complex due to its inability to bind β2M and be transferred to the
cell surface, it does not interact with TfR, thus resulting in more
iron uptake than WT-HFE (Feder et al., 1997; Waheed et al., 1999,
2002). In sum, both variants are associated with cell and tissue
iron-overload. For more details see Connor and Lee (2006).
In addition to the increased iron accumulation seen in cells
expressing H63D-HFE (Lee et al., 2007; Mitchell et al., 2009b),
disruption of mitochondrial potential (Lee et al., 2007), increased
inﬂux of intracellular Ca2+ (Mitchell et al., 2009b), increased
glutamate uptake (Mitchell et al., 2009b), increased secretion of
monocyte chemoattractant protein-1 (MCP1) that has a role in
neuroinﬂammation (Mitchell et al., 2009a), increased ER stress
(Liu et al., 2011), increased oxidative stress (Lee et al., 2007),
increased toxicity to Aβ (Mairuae et al., 2010), and decreased
Pin1 activity (Hall et al., 2010) that contributes to increased Tau
phosphorylation (Hall et al., 2011) are also found. These ﬁndings
demonstrate that the expression of H63D-HFE creates a permis-
sive milieu for processes that can inﬂuence other pathways in
neuronal cells such as lipid homeostasis, neurotransmission, and
myelination that may ultimately lead to AD.
LIPID DYSHOMEOSTASIS IN NEURODEGENERATIVE
DISEASES
CHOLESTEROL METABOLISM IN THE BRAIN
Cholesterol is an essential component of all cell membranes and is
needed for maintaining their structure and ﬂuidity. It is required
for growth and replication of mammalian cells, exo- and endo-
cytosis, and is a precursor of steroid hormones and bile acids.
Cholesterol is synthesized in the liver through a series of reac-
tions with the rate-limiting step catalyzed by HMGCoAR which
catalyzes conversion of HMG-CoA to mevalonic acid. Choles-
terol is transported to organs other than the brain in the form
of lipoproteins. In the brain, almost all of its cholesterol is syn-
thesized in situ, with little to none taken up from the circulation.
The insulation of brain from changes in circulating cholesterol
is achieved by the blood–brain barrier (BBB). The highest rate
of cholesterol synthesis in the CNS occurs during early stages of
development especially when myelination is occurring (Jurevics
and Morell, 1995, 1997). The mature brain continues to synthe-
size cholesterol but at lower levels (Mcmillan et al., 1972; Boyles
et al., 1985). The ﬁnding that the half-life of cholesterol in the
adult human brain is approximately 5 years, indicates that it must
have an efﬁcient cholesterol recyclingmechanism (Bjorkhem et al.,
1998).
In the brain, oligodendrocytes, astrocytes and neurons are
capable of synthesizing cholesterol (Saito et al., 1987; Suzuki
et al., 2007). Most of the cholesterol synthesized by oligoden-
drocytes is found in myelin. Neurons have a high need for
cholesterol due to membrane turnover during synaptic trans-
mission. Instead of synthesizing their own, neurons obtain
most of their cholesterol from astrocytes (Srivastava et al., 1997;
Stone et al., 1997) which when packaged with ApoE, also syn-
thesized by astrocytes (Pitas et al., 1987a,b; Schmechel, 1993;
LaDu, 1998; Dolev and Michaelson, 2004), is delivered to neu-
rons where it is bound by cell surface lipoprotein receptors
such as low density lipoprotein receptor (LDLR) and LDLR-
related protein 1 (LRP1) that recognize ApoE prior to endocyto-
sis. Though other apolipoproteins are also found in the CNS, i.e.,
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Apo AI, ApoJ, ApoD, evidence suggests that ApoE is highly abun-
dant in the brain and is responsible for the shuttling of cholesterol
between astrocytes and neurons (Bjorkhem and Meaney, 2004). A
schematic depicting cholesterol metabolism in the CNS is shown
in Figure 1.
In addition to recycling of cholesterol, there is need for removal
of excess cholesterol from the brain. Due to its hydrophobic nature,
cholesterol cannot cross the BBB. Two mechanisms have been
proposed for its removal; cholesterol hydroxylation and ApoE-
dependent efﬂux. The presence of ApoE-bound cholesterol in the
CSF indicates that some excretion of brain cholesterol occurs this
way but the mechanism is not understood. Based on the rate of
CSF renewal and the amount of cholesterol found in the CSF, it has
been estimated that 1–2mg cholesterolmay be eliminated from the
brain via the CSF each day (Pitas et al., 1987a). The major mech-
anism of cholesterol clearance from the brain is its conversion
by the enzyme cholesterol 24-hydroxylase (CYP46A1) to 24S-
hydroxycholesterol (24S-HC), a metabolite that can traverse the
BBB (Lutjohann et al., 1996; Bjorkhem et al., 1997, 1998). Intro-
duction of the hydroxyl group in the side chain of the cholesterol
molecule causes a rearrangement of membrane phospholipids
that allows excretion of the oxysterol in an energetically favor-
able manner (Kessel et al., 2001). The direction of movement is
mediated by the concentration gradient (Bjorkhem and Meaney,
2004). Because almost all of the 24S-HC originates from the
brain, it has been suggested that it can be used as a marker of
brain cholesterol homeostasis. Consistent with this view, a num-
ber of studies have shown altered levels of 24S-HC in the CSF or
plasma of patients with neurological diseases such as AD and mul-
tiple sclerosis (MS; Bretillon et al., 2000a; Lutjohann et al., 2000;
Leoni et al., 2002). These studies also highlight the importance
of a normal ﬂux of cholesterol across the CNS that for healthy
humans is approximately 0.09 mg/day per kg (Saito et al., 1987)
and1.4mg/day per kg inmice (Panzenboeck et al., 2002). In people
with AD cholesterol efﬂux across the CNS is elevated and is pro-
portional to the severity of dementia (Pfrieger, 2003a). A similar
trend was observed in a mouse model of Niemann Pick C1 disease
(NPC1), where the increase in cholesterol efﬂux from the brain
was associated with increased neurodegeneration (Panzenboeck
et al., 2002).
ROLE OF CHOLESTEROL IN THE BRAIN
Two major functions for cholesterol in the nervous system are in
myelination and synaptic transmission. In addition, it is an essen-
tial constituent of cellular membranes and of detergent insoluble
lipid rafts, areas enriched in sphingolipids and proteins involved
in signal transduction, where it can inﬂuence signal transduction
and cellular processes. The importance of cholesterol in the brain
is evident from the fact that it has ∼25% of the body’s cholesterol
(BjorkhemandMeaney,2004). In the brain, cholesterol is enriched
in myelin (i.e., oligodendroglia) and is an essential component
of membranes of all cells. Notably, myelin consists of ∼70%
lipids [mostly cholesterol, phospholipids, and glycosphingolipids
(GSLs), i.e., galactocerebroside in molar ratios of ∼4:4:2] and 30%
proteins (Bjorkhem and Meaney, 2004). The high lipid content of
myelin is consistent with the membrane properties required for
its role in supporting saltatory conduction. Myelin is produced
by oligodendrocytes (Miller, 2002) and cholesterol enrichment in
myelin reduces permeability to ions allowing the action potential
to move down the axon without diffusing across the membrane
(Bjorkhem and Meaney, 2004). It has been shown that a high
cholesterol content is needed for proper myelination (Saher et al.,
2005). A deﬁciency in oligodendrocyte cholesterol synthesis was
shown to delay proper myelination (Marcus and Popko, 2002;
Saher et al., 2005) and to be crucial for the development and
maintenance of myelin membranes (Colognato et al., 2002; Gielen
et al., 2006; Debruin and Harauz, 2007). Low cholesterol levels in
an aging brain could contribute to the loss of myelination that
Bartzokis (2011) postulated was an underlying cause of multiple
degenerative brain disorders.
Cholesterol content of a membrane regulates its ﬂuidity with
greater amounts of cholesterol making them more rigid and lesser
amounts making them more ﬂuid and allowing more permeabil-
ity to ions (Barenholz, 2002). Therefore, disruption of cholesterol
distribution in the membrane can affect its function in maintain-
ing normal cell activity. Consistent with this view, altered dendritic
FIGURE 1 | Neuronal acquisition/loss of cholesterol. Cholesterol
synthesized by astrocytes is packaged in lipoproteins containing ApoE,
released from the cell and taken up by neurons via the lipoprotein
receptor-related protein 1 (LRP1)-mediated endocytosis. Cholesterol can be
removed by conversion to 24S-hydroxycholesterol, a compound that can
cross the BBB, by the action of cholesterol 24-hydroxylase.
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morphology was observed upon depletion of membrane choles-
terol in cultured neurons (Holtzman et al., 1995). Disruption of
lipid homeostasis signiﬁcantly alters CNS structure and function
possibly by affecting the composition of lipid rafts found in neu-
rons, astrocytes, and oligodendrocytes (Tsui-Pierchala et al., 2002;
Gielen et al., 2006; Debruin and Harauz, 2007). Changes in choles-
terol concentration can also affect cell surface availability of the
carbohydrate moieties of GSLs (Novak et al., 2013) which in turn
might affect a cell’s ability to respond toGSL-carbohydrate binding
proteins.
Several studies have shown that cholesterol is needed for endo-
and exocytosis and plays a crucial role in synapse structure and
function (Pfrieger, 2003b; Takamori et al., 2006). Consistent with
this, cholesterol is enriched in presynaptic terminals and its phar-
macological depletion reduces synaptic transmission (Suzuki et al.,
2004). Several key synaptic proteins such as synaptophysin and
the soluble NSF attachment protein receptor (SNARE) proteins
are either predominantly found in lipid rafts or must be recruited
into them in order to effectively interact with other proteins to
promote neurotransmitter release and transmission. These effects
are thought to be mediated by direct interaction of cholesterol
with synaptophysin (Thiele et al., 2000), and formation of the
SNARE complex is cholesterol-dependent (Lang et al., 2001; Mit-
ter et al., 2003). Moreover, Suzuki et al. (2007) showed that an
increase in the cholesterol content of lipid rafts, induced by treat-
ment with brain derived neurotropic factor (BDNF), resulted
in increased expression of raft-associated presynaptic proteins,
changes associated with synapse development. Collectively, these
studies highlight the importance of cholesterol in regulating
expression of synaptic proteins and for synaptic transmission.
BRAIN vs. PLASMA CHOLESTEROL IN AD
Findings regarding cholesterol content in the plasma of aging and
AD individuals are inconsistentwith regards towhether elevatedor
lower serum cholesterol is a risk factor for AD. A consistent obser-
vation in human studies is that high serum cholesterol in mid-life
can increase the risk of developing AD later in life, but is asso-
ciated with improved cognition in elderly individuals (Schreurs,
2010). Similarly, lower total serum cholesterol (Kim et al., 2002)
and lower high density lipoprotein (HDL) cholesterol were found
to be associated with poor cognition in the elderly (Atzmon et al.,
2002). However, status of brain cholesterol could be a better pre-
dictor of AD pathogenesis. With regard to the exchangeability
between serum and brain cholesterol, the idea that under nor-
mal conditions cholesterol from serum does not cross the BBB
into the brain is well-established. Support for this concept was
provided by studies showing no incorporation of label into lipids
of the brain or spinal cord after administration of D2O to adult
rats (Waelsch et al., 1940). These ﬁndings have been replicated by
several investigators (Jurevics and Morell, 1995; Dietschy and Tur-
ley, 2001). Intravenous injections of 14C-labeled cholesterol into
healthy volunteers and pregnant women resulted in no label being
found in the brains of the healthy volunteers (Meaney et al., 2001)
or fetal brain tissue (Plotz et al., 1968), emphasizing that almost
all cholesterol in the brain comes from de novo synthesis with lit-
tle to none from plasma under normal physiological conditions.
Surprisingly, brain endothelial cells have been shown to take up
a small amount of LDL cholesterol via LDL receptors expressed
on their luminal surface (Dehouck et al., 1994, 1997). It has been
hypothesized that uptake of small amounts of plasma lipoproteins
into the CNS could occur at levels too low to be detected by cur-
rent methods (Dietschy and Turley, 2001). However, signiﬁcant
uptake of cholesterol from plasma could occur under patholog-
ical conditions where the integrity of the BBB is compromised
or in cases of chronic hypercholesterolemia. This possibility is
supported by studies showing a number of metabolic changes in
the brains of individuals/experimental animals fed diets high in
cholesterol. Currently, knowledge is limited in this respect and fur-
ther studies are needed to elucidate the effects of dietary cholesterol
on brain cholesterol, especially in cases of neurological disease.
CHOLESTEROL HOMEOSTASIS AND AD PATHOLOGY
There is substantial epidemiological, genetic, and molecular evi-
dence of disruption of cholesterol homeostasis in AD (Shobab
et al., 2005; Sjogren et al., 2006). Mutations in several genes
involved in cholesterol uptake, such as LRP and the very-low-
density lipoprotein (VLDL) receptor (Zerbinatti and Bu, 2005),
as well as in enzymes that regulate cholesterol catabolism such as
Cyp46A1 (Wolozin, 2003; Vaya and Schipper, 2007), have been
associated with increased risk of AD. In addition epidemiologi-
cal studies revealed increased susceptibility to AD in patients with
elevated plasma cholesterol levels in mid-life (Jarvik et al., 1995;
Notkola et al., 1998; Roher et al., 1999). However, studies of choles-
terol in brains obtained from animals with AD symptoms and
AD human brain autopsy tissue have yielded inconclusive results
regarding whether high or low brain cholesterol is a risk factor for
AD. The lack of agreement between studies could be due to analy-
sis of cholesterol content fromdifferent regions/domains, i.e., total
brain cholesterol vs. membrane cholesterol vs. cholesterol in lipid
raft domains. It has been reported that while the asymmetric dis-
tribution of cholesterol in the plasma membrane of aged mice was
reduced relative to that of younger mice, total membrane choles-
terol was unaltered (Igbavboa et al., 1996). However, cholesterol
content of lipid rafts from brains of older mice expressing either
human ApoE3 or ApoE4 was greater than in those from brains of
younger animals (Igbavboa et al., 2005). It has also been reported
that brain cholesterol increases in certain conditions with age, i.e.,
NPC1 (Vance, 2006) while studies of other conditions provided
evidence for a decline in total brain cholesterol, i.e., AD (Ledesma,
2003) and Huntington’s disease (Valenza et al., 2005). In addition
to total brain cholesterol, maintenance of cellular cholesterol con-
tent is crucial in mediating APP processing via alpha and gamma
secretases (Bogdanovic et al., 2002; Cam and Bu, 2006) and there-
fore has physiological relevance to AD. Ginsberg et al. (1993a,b)
have shown that in AD brains cell membranes are less stable due
to altered lipid composition. In sum, experimental studies have
shown that either abnormally highor lowcholesterol canbe associ-
ated with pathogenic manifestations seen in neurological diseases.
Excessive loss of brain cholesterol would be expected to be partic-
ularly devastating because the rate of cholesterol synthesis in the
brain decreases with age and under normal conditions there is no
inﬂux of cholesterol from the plasma into the brain.
ApoE is a major apolipoprotein and cholesterol carrier in the
brain (Mahley, 1988). It is synthesized and secreted primarily from
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astrocytes as part of small dense cholesterol containing lipopro-
teins (Pitas et al., 1987a,b; Schmechel, 1993; LaDu, 1998; Dolev
and Michaelson, 2004). Neurons take up astrocyte-released ApoE
via LRP1 mediated endocytosis (Herz, 1988; Jeon and Blacklow,
2005). In humans, ApoE exists as three isoforms (E2, E3, E4;
Mahley, 1988). The association of ApoE4 as a strong risk factor for
AD has been well established (Mahley, 1988; Corder, 1993; Mahley
et al., 2006). Despite advances in understanding how ApoE func-
tions, the molecular mechanisms by which ApoE4 contributes to
AD are not completely understood. In the general population,
ApoE3 is the most common isoform (allele frequency 77–78%),
followed by ApoE4 (15%; Mahley, 1988). However, ApoE4 is
present in ∼40% of AD patients (Corder, 1993). Isoform-speciﬁc
effects in cholesterol transport were observed with ApoE4 being
less efﬁcient thanApoE3 (Michikawa et al.,2000; Gong,2002; Rapp
et al., 2006). There is also evidence that ApoE3-expressing astro-
cytes can supplymore cholesterol to neurons than those expressing
ApoE4 (Gong, 2002). Recent reports about the ability of neurons
to recycle ApoE and retain ApoE inside cells (Fazio et al., 2000)
have led to the hypothesis that ApoE may play additional roles in
mediating cell signaling and intracellular-homeostasis. One pro-
posed role, that of an antioxidant, is based on its ability to bind
metals such as copper, iron, and zinc, with its highest binding
afﬁnity being for iron (Miyata and Smith, 1996). Interestingly, the
antioxidant and metal binding activities of ApoE were found to be
allele-speciﬁc, with ApoE4 less efﬁcient in binding metals (Mutter
et al., 2004) and reducing oxidative stress than ApoE3 (Miyata and
Smith, 1996).
SPHINGOLIPIDS IN NEURODEGENERATIVE DISEASES
Sphingolipids contain sphingosine as their basic building block
and are enriched in lipid rafts. When substituted with a fatty acid
in an amide linkage on C2, ceramide is produced that when linked
to phosphorylcholine yields sphingomyelin and when glycosy-
lated yields a GSL. Sphingolipids function in cell–cell recognition,
signaling cascades that result in cell proliferation, apoptosis,
stress responses, inﬂammation, differentiation, and axon growth
(Venable et al., 1995; Hannun and Obeid, 2002; Spiegel and Mil-
stien, 2002; Lavieu et al., 2006; Snider et al., 2010). Unequivocal
evidence for the need for appropriate synthesis of sialylated GSLs
was provided by the ﬁnding that brains of children who lacked
the ability to synthesize GM3 failed to develop normally (Simp-
son et al., 2004). Dysregulation of GSL metabolism has also
been implicated in a number of metabolic and neurological dis-
eases such as Fabry disease, Krabbe disease, Gaucher disease,
Tay-Sachs disease, Metachromatic leukodystrophy, Niemann-Pick
disease, AD (Haughey et al., 2010; He et al., 2010; Ryland et al.,
2011).
Several studies have shown abnormalities in the lipid content
and expression of enzymes regulating their content in AD brains.
For example, the total phospholipid and sulfatide content in AD
brains was decreased compared to that in controls (Skinner et al.,
1989; Soderberg et al., 1992; Gottfries et al., 1996; Pettegrew et al.,
2001; Han et al., 2002; Cheng et al., 2003). On the other hand,
ceramide, a pro-apoptotic lipid was found to be elevated in the
brains (Cutler et al., 2004) andCSFof patientswithAD(Satoi et al.,
2005). Ceramide can be produced by hydrolysis of sphingomyelin
via sphingomyelinases, or by de novo synthesis from fatty acyl CoA
and sphingosine. It has been proposed that oxidative stress and
other age-related factors contribute to the age-related accumula-
tion of ceramide and induction of apoptotic signaling in neurons
and other cells (Kolesnick and Kronke, 1998; Cutler et al., 2004;
Costantini et al., 2005; Perez et al., 2005). He et al. (2010) replicated
the ﬁndings of a reduction in sphingomyelin and an elevation of
ceramide in AD brains made by Satoi et al. (2005). In addition,
they also found reduced levels of sphingosine-1-phosphate (S1P),
a pro-survival metabolite, which correlated signiﬁcantly with the
levels of Aβ peptide and hyperphosphorylated tau protein (He
et al., 2010).
In addition to the sphingolipids mentioned above, the relation-
ship of gangliosides, a sub-class of GSLs, to AD pathogenesis has
been investigated. Gangliosides are found in their highest con-
centration in the gray matter of the brain, with GM1, GD1a,
GD1b, and GT1b accounting for 65–85% of them (Schengrund,
2010). Interestingly, total ganglioside content was found to be
reduced in most regions of brains from early onset or familial
cases of AD,while in cases of late-onset or sporadicAD,ganglioside
reduction was observed only in the temporal cortex, hippocam-
pus and frontal white matter (Svennerholm and Gottfries, 1994).
These observations suggest an age-dependent and/or region-
speciﬁc pattern of distribution that could be differentially altered
in AD.
Though reduction of total brain ganglioside levels in AD has
been reported, signiﬁcant elevation of certain ganglioside species
has also been consistently reported. For example, GM1, one of
the major gangliosides in brain that is enriched in lipid rafts,
was found to be signiﬁcantly elevated in brains of AD patients
(Svennerholm and Gottfries, 1994) and, in lipid rafts isolated from
their frontal and temporal cortices (Molander-Melin et al., 2005)
A similar observation was made in a neuroblastoma cells express-
ing the H63D-HFE variant (Ali-Rahmani et al., 2014a) suggesting
these changes are driven by HFE genotype and that a model for
determining the mechanism for HFE impact on lipid rafts exists
Additional support for the role of gangliosides in AD was pro-
vided by the observation thatGM1 stimulated production of Aβ by
increasing γ-secretase activity (Zha et al., 2004), that it binds to Aβ
with high afﬁnity (Ariga et al., 2001), and could serve as a “seed”
for Aβ aggregation by promoting formation of toxic Aβ ﬁbrils
(Choo-Smith et al., 1997; Yanagisawa, 2005; Kimura and Yanag-
isawa, 2007; Okada et al., 2007; Yamamoto et al., 2007). Indeed,
GM1 was found bound to Aβ in amyloid plaques in AD brains
(Hayashi et al., 2004). It has also been shown to inﬂuence AD
pathogenesis by altering calcium homeostasis. It has been shown
that plasma membrane-associated GM1 can enhance intracellular
Ca2+ levels by increasing inﬂux of extracellular Ca2+ (Ledeen and
Wu, 2002; Wu et al., 2007) which might affect calcium-mediated
phosphorylation of tau and APP (Schengrund, 2010). In addition
to affectingAPP andCa2+ homeostasis, GM1has been found to be
associated with altered content of other lipids such as cholesterol.
Molander-Melin et al. (2005) reported that an elevation of GM1
and GM2 in lipid rafts isolated from AD brains was associated
with a concomitant decrease in their cholesterol (Molander-Melin
et al., 2005). Similarly, pharmacological depletion of cholesterol
in murine neuroblastoma cells resulted in a signiﬁcant elevation
Frontiers in Pharmacology | Drug Metabolism andTransport July 2014 | Volume 5 | Article 165 | 6
Ali-Rahmani et al. Iron, cholesterol, and neurodegeneration
in the recognition of GM1 (Petro and Schengrund, 2007), sug-
gesting an inverse relationship between GM1 and cholesterol. The
fact that both lipids are present in rafts supports the hypothesis
that signiﬁcant changes in either or both could affect the ability of
rafts tomodulate a number of cellular processes affecting neuronal
function. Collectively, these studies show that sphingolipids play
important roles inAD pathogenesis. Further elucidation of factors
that can inﬂuence sphingolipid composition is needed. Factors
inducing oxidative stress such as iron are potential targets. Future
investigation in this area will further our understanding of the
connection between iron and lipid metabolism and will help in
development of better treatment strategies.
LIPID RAFTS IN AD
Given the abundance of cholesterol and sphingolipids in the brain,
lipid rafts have been proposed as critical for regulating processes
such as neuronal signaling, neuronal cell adhesion, axon guidance
and neurotransmission required for normal brain function. Rafts
have been shown to facilitate intramembrane proteolysis to acti-
vate or inactivate several transmembrane proteins such as APP
and receptors involved in neurotrophin signaling (Landman and
Kim, 2004; Vetrivel et al., 2005). In addition, ionotropic recep-
tors, pre-synaptic SNARE complex proteins (i.e., synaptophysin),
as well as, post synaptic receptors [such as N-methyl-D-aspartic
acid (NMDA) and gamma-aminobutyric acid (GABA)], and key
proteins involved in myelination (i.e., CNPase, MBP) are known
to localize in lipid rafts and modulation of lipid raft composi-
tion has been shown to affect their function (Marta et al., 2004;
Stetzkowski-Marden et al., 2006; Willmann et al., 2006; Besshoh
et al., 2007; Huang et al., 2007). Changes in the composition of
rafts by depletion of cholesterol or sphingolipids can affect the
structure (assembly and disassembly) and function of lipid rafts
and ultimately, cellular phenotype (Keller et al., 2004; Veatch and
Keller, 2005). Evidence is also accumulating to support the con-
cept that there is a dynamic equilibrium between cholesterol and
sphingolipids within the rafts and that when levels of one of these
components is altered it affects the concentration of the other
(Ali-Rahmani et al., 2011).
The roles of lipid rafts in the brain have been under intense
investigation, particularly in the context of neurodegenerative dis-
eases. Relevant to AD are studies showing loss of lipid rafts in the
temporal cortex (Molander-Melin et al., 2005) and reduced choles-
terol in rafts isolated from hippocampi of AD patients (Ledesma,
2003; Abad-Rodriguez et al., 2004). These observations are con-
sistent with ﬁndings of signiﬁcant loss of total brain cholesterol in
advanced stage AD patients (Abad-Rodriguez et al., 2004). Studies
focused on investigating the role of lipid rafts and their cholesterol
content in amyloidogenesis have yielded conﬂicting results. Analy-
ses of the effect of changes in the cholesterol content of lipid rafts,
sites where APP and presenilin−1 (enzyme that cleaves APP to
generate toxic Aβ) localize or are recruited to in order to promote
amyloidogenesis, indicated that a high cholesterol content favored
it (Bouillot et al., 1996; Lee et al., 1998; Morishima-Kawashima
and Ihara, 1998; Hayashi et al., 2000). In contrast studies in which
cholesterol was depleted from neuronal cells expressing human
APP resulted in colocalization of presenilin-1 and APP in non-
raft domains and increasedAβ production (Abad-Rodriguez et al.,
2004). These ﬁndings along with the evidence of low total brain
cholesterol in AD patients support the hypothesis that therapeutic
approaches designed to lower brain cholesterol could be detri-
mental to normal brain function. In fact, accumulating evidence
indicates that loss of cholesterol can promote neurodegeneration
as lower serum/total brain/membrane cholesterol have been impli-
cated in increased risk of Parkinson’s (Du et al., 2012),ALS (Albert,
2008; Chio et al., 2009), Smith–Lemli–Opitz syndrome (Jira et al.,
2003), Huntington’s (Valenza et al., 2005), Alzheimer’s (Ledesma,
2003; Wellington, 2004; Wolozin, 2004), and Niemann–Pick Type
C (Vance, 2006) diseases. In summary, lipid rafts modulate a
number of cellular processes that affect neuronal function and
alterations in their composition (cholesterol and sphingolipid con-
tent) can inﬂuence cellular phenotype. Investigation of lipid rafts
in the context of iron related disorders such as HH, AD, and iron
deﬁciency anemia are exciting new areas of research which should
be further explored to unravel potential signaling pathways under-
lying iron related disorders that might be treated by modulation
of the lipid composition of rafts.
IS THERE A LINK BETWEEN IRON AND CHOLESTEROL
METABOLISM?
Contribution of iron to neurodegeneration in AD has also been
proposed to occur based on its ability to inﬂuence four path-
ways implicated in AD: (1) APP metabolism (Mantyh et al., 1993;
Bodovitz et al., 1995; Schubert andChevion, 1995; Rottkamp et al.,
2001; Rogers et al., 2002; Kuperstein and Yavin, 2003), (2), the
loss of calcium homeostasis (Hidalgo and Nunez, 2007), (3) the
degradation of a subset of microglia (Lopes et al., 2008), and (4)
oxidative stress (Honda et al., 2004; Liu et al., 2006; Smith, 2006;
Castellani et al., 2007, 2012). Here we propose that the effect of
iron on lipid metabolism is also a potential contributor to AD.
Despite the efforts that have been made to identify factors
that can trigger the pathological events associated with AD the
sequence of events is still not clear. Accumulation of Aβ has been
thought to be the triggering event, preceding NFT formation, and
ultimately culminating in synaptic failure and memory impair-
ment. However, other evidence indicates that tau pathology may
precede formation of amyloid plaques. The evidence of memory
decline accompanied by symptoms characteristic of AD, in the
absence of amyloid plaques and/or NFTs, supports questioning
whether these pathological markers are the only causative agents.
Since molecular phenotypes such as oxidative stress, synaptic fail-
ure, neuronal loss, and cognitive decline, characteristics associated
with AD, have been shown to result from disruption of a number
of the pathways discussed above, one can easily argue that there is
no linear sequence of events that causes AD. A good example of an
interconnection between pathways that may have relevance to AD
lies at the intersection between iron and cholesterol metabolism.
Both iron and cholesterol metabolism have been independently
implicated in the etiology of AD as described above. A large
number of studies have established that disruption of cholesterol
metabolism is associated with multiple aspects of AD, including
APP metabolism, Tau phosphorylation, synaptic integrity and
transmission, and cognitive function. Iron dyshomeostasis has
also been shown to contribute to the above-mentioned aspects
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of AD, suggesting an interactive cross-talk between the two path-
ways that may result in synergistic deleterious effects contributing
to the development of AD. Evidence is accumulating for a poten-
tial link between iron and cholesterol metabolism in the context of
atherosclerosis, yet this link and its relevance toAD remains largely
unexplored. There is some evidence to support this association.
(1) Iron is a required cofactor for a number of enzymes involved in
cholesterol metabolism so it is logical to speculate that alteration
in iron content could inﬂuence the activity of those enzymes. (2)
Iron, ApoE, and cholesterol have all been found in association
with extracellular amyloid plaques and intracellular neuroﬁbril-
lary tangles, hallmark features of AD. (3) Iron is a potent source
of oxidative radicals that have been consistently reported to affect
membrane lipids and thereby inﬂuence lipid homeostasis. (4)Rab-
bits fed a cholesterol-rich diet were found to accumulate iron and
Aβ deposits in the brain, and to have increased mortality (Ghribi
et al., 2006). Finally, and perhaps most relevant are the recent ﬁnd-
ings that carriers of both theApoE4 (cholesterol transporter) allele
and H63D-HFE variant (iron accumulation, cholesterol decrease)
had increased risk for and 5.5 year earlier onset of AD (Moalem
et al., 2000; Sampietro et al., 2001; Combarros et al., 2003; Percy
et al., 2008). Collectively, these studies highlight an area of investi-
gation that could lead to a better understanding of the underlying
causes for AD and impact the 25% of the Caucasian population
that carries at least one H63D allele.
The ﬁnding that carriers of both the H63D-HFE and ApoE4
alleles have an earlier onset of AD (Percy et al., 2008) indicates that
there is a connection between iron, cholesterol, and AD; however,
the interaction of iron and cholesterol and its relevance to AD had
not been speciﬁcally investigated prior toour studies of the effect of
H63D-HFE on both (Ali-Rahmani et al., 2014a). While the H63D-
HFE-expressing neuroblastoma cells had increased iron content
and iron is a required cofactor for a number of enzymes involved
in cholesterol synthesis (e.g., HMGCoAR and squalene synthase),
the cells expressed less HMGCoAR and had less total cholesterol
than WT-HFE-expressing controls. They also had an increased
expression of CYP46A1 (Ali-Rahmani et al., 2014a). These obser-
vations were recapitulated in studies of the brains of H67D-HFE
mice. Brain cholesterol content of H67D-HFE mice was signiﬁ-
cantly higher in 6 month old mice, however as these mice aged
their brain cholesterol content continued to decline much more
than in WT-HFE mice (Figure 2). Strikingly, a signiﬁcant negative
correlation was found between brain iron and cholesterol con-
tent for H67D-HFE mice ages 12–24 months (Ali-Rahmani et al.,
2014a). These mice had higher total brain iron content and lower
brain cholesterol content than their wild-type littermates. These
results are similar to the association foundbetween increased brain
(nigrostriatal) iron content and low serum cholesterol in patients
withParkinson’s disease (Duet al., 2012). Though it is believed that
cholesterol content of serum is not necessarily reﬂective of that of
brain, it is important to note that in another study it was shown
that patients with high serum iron and low serum cholesterol had
the highest risk of PD (Powers et al., 2009), indicating the rele-
vance of the interplay between iron and cholesterol metabolism in
a neurodegenerative disease.
An inverse relationship between iron and cholesterol content
was also observed in several additional studies. For example,
FIGURE 2 |Total brain cholesterol content of mice expressingWT- or
H67D-HFE. Brains were dissected from mice at 6, 12, 18, and 24 months.
After homogenization, protein concentration was determined by Bradford
assay (n = 7–17 per group including both male and female mice). Lipids
were extracted from 100 μl of brain homogenate. Cholesterol content was
measured by following the manufacturer’s protocol (Biovision), and is
shown as μg of cholesterol per mg of protein (***p < 0.001). Data were
analyzed using a two-way ANOVA followed by Bonferroni tests to compare
effects of age and genotype on age-related changes in brain cholesterol of
HFE variant mice using Graphpad (Prism) software. Error bars represent the
standard error of the mean.
Brunet et al. (1997) found that treatment of rats with an iron-
salicylate complex resulted in an elevation of iron, products of
lipid peroxidation, and reduced total serum cholesterol. Treat-
ment of rats with an iron dextran complex resulted in an elevation
of iron and a decrease in total serum cholesterol regardless of
whether the rats were fed a normal diet or one high in cholesterol
(Turbino-Ribeiro et al., 2003). Similar results were found in earlier
studies in which rabbits treated with an iron dextran complex and
fed a normal diet were found to have reduced serum cholesterol
(Dabbagh et al., 1997). In fact, diet-induced iron overload resulted
in reduced expression of liver HMGCoAR and CYP7A1 (Brunet
et al., 1999).
One possible explanation for the effects of a high iron diet is
that they are mediated by iron-induced oxidative stress (Dabbagh
et al., 1994) and lipid peroxidation (Britton et al., 1987). Deple-
tion of energy (ATP and NADPH) due to oxidative stress and
lipid-peroxidation mediated membrane damage were shown to
cause disruption of lipid synthesis and transport (Kehrer, 1993).
These observations coupled with the inverse relationship between
iron and cholesterol described above support the hypothesis that
the changes induced in iron and cholesterol by expression of
H63D-HFE and possibly additional mediators disrupt the nor-
mal neuronal function. One possible molecule involved in these
interactions is Aβ. The presence of the iron response element
(IRE) in the promoter region of the APP gene and the observa-
tion of an iron-concentration dependent increase in APP mRNA
provides compelling evidence for the role of iron in APP expres-
sion and possibly Aβ generation (Bodovitz et al., 1995; Rogers
et al., 2002; Rogers and Lahiri, 2004). Interestingly, there is also
evidence that Aβ can, in turn, modulate cholesterol and sphin-
golipidmetabolismby regulating the activities of key lipid enzymes
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(Zinser et al., 2007; Grimm et al., 2012). Speciﬁcally, Aβ has been
shown to inhibit cholesterol synthesis by inhibiting HMGCoAR
(Grimm et al., 2012), suggesting that a feedback mechanism exists
between cellular cholesterol and Aβ content. Furthermore, GM1
has been shown to serve as a “seed” for Aβ aggregation into
toxic ﬁbrils (Hayashi et al., 2004; Yanagisawa, 2005; Okada et al.,
2007). Intriguingly, there is evidence that an increase in GM1, or
a change in its accessibility to GM1-binding proteins can occur
upon reduction of cellular cholesterol (Lingwood et al., 2011). A
link for a relationship between iron, cholesterol, and GM1, was
provided by our ﬁnding that H63D-HFE human neuroblastoma
cells containedmore iron (Lee et al., 2007), expressedmore cholera
toxin binding GM1 (Ali-Rahmani et al., 2011) and had less choles-
terol than cells expressing WT-HFE (Ali-Rahmani et al., 2014a).
Taken together, our ﬁndings and the studies of the role of APP
metabolism in AD and its relationship to either iron or choles-
terol, provide the basis for the proposed mechanism (Figure 3) by
which effects induced by expression of H63D-HFE may lead to the
symptoms associated with AD.
With the exception of Aβ content, all of the pathological effects
indicated in this model have been observed in either cells express-
ing H63D-HFE or in the brains of mice expressing H67D-HFE.
Cellular studies indicated no difference in the levels of total APP or
Aβ between WT- and H63D-HFE-expressing cells, but increased
sensitivity to Aβ treatment was observed in the latter (Mairuae
et al., 2010). Further study of the age-related effects of expres-
sion of the H63D variant on APP metabolism in an in vivo model
should further deﬁne the interrelationships of HFE,APP, iron, and
cholesterol metabolism, and the mechanisms by which they may
contribute to dementia.
As important as it is to study the impact of iron overload
on lipid metabolism, the question of what impact high serum
and/brain cholesterol levels might have on iron metabolism in
the brain should also be investigated. Such a study might help to
explain the (1) established link between hypercholesterolemia and
atherosclerosis and the fact that they both are signiﬁcant risk fac-
tors forAD,(2) connectionbetweendisruptionof ironmetabolism
and atherosclerosis, and (3) impact of a cholesterol enriched diet
on iron management. Results from studies in rabbits that were
fed a diet high in cholesterol showed an increase in iron accu-
mulation in the brain (Ong and Halliwell, 2004; Ong et al., 2004;
Ghribi et al., 2006) and an elevation of lipid peroxidation prod-
ucts (De La Cruz et al., 2000; Gokkusu and Mostafazadeh, 2003).
Though passage of dietary cholesterol into the brain is prohibited
by the BBB, some metabolites, small molecules, and inﬂammatory
cytokines produced by chronic hypercholesterolemia may be able
FIGURE 3 | Effects of the expression H63D-HFE and how they may lead
to AD.We propose that (1) the increase in brain iron induced by the
expression of H63D-HFE is initially compensated for by an elevation in brain
cholesterol. (2) The elevated iron and cholesterol then synergistically enhance
Aβ accumulation and together induce oxidative stress and lipid peroxidation.
As the cycle of increased iron, increased Aβ and inhibition of cholesterol
synthesis continues, the levels of oxidative radicals supersede the cell’s
antioxidant capacity. This affects mitochondrial function, enhances secretion
of inﬂammatory cytokines and other toxic radicals, increases tau
phosphorylation, intracellular Ca2+, and GM1. (3) As iron accumulation and
the concomitant changes it induces occur they start to alter expression
of enzymes involved in cholesterol metabolism thereby reducing its
concentration. (4) In an effort to survive, cells adapt to a state of low
cholesterol content in an effort to limit Aβ production. (5) Over time, due to
decreased cholesterol and damage induced by oxidative radicals and other
changes, myelin and eventually synapses disintegrate leading to cell death.
The resultant neuronal loss would then impair memory function culminating
in AD.
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to cross from the circulation into the BBB and eventually alter the
permeability of the BBB to other harmful substances. The obser-
vation of iron accumulation in the brain after long-term feeding
of a high-cholesterol diet provides support for this argument and
raises the question of whether and/or how hypercholesterolemia
allows increased passage of iron into the brain parenchyma. The
next logical question is then how would individuals with H63D-
HFE be affected by these changes? We know that individuals with
H63D-HFE have elevated iron levels in liver as well as in the brain
(Waheed et al., 1997; Adams et al., 2005; Bartzokis et al., 2010). If
these individuals develop hypercholesterolemia, they could have
even more passage of iron into the brain,more oxidative stress and
other disease-associated consequences. Interestingly, it has been
shown that individuals with the ApoE4 allele have high serum
cholesterol and an increased incidence of hypercholesterolemia.
This observation may provide an explanation for why individu-
als with both ApoE4 and H63D-HFE have an increased risk and
earlier onset of AD. Further elucidation of this mechanism would
provide an explanation for why atherosclerosis and hypercholes-
terolemia, conditions prevalent in many aging individuals, may
contribute to the development of AD. In relation to that, studies
aimed at teasing out the effects of diet (high-iron or high choles-
terol, or both) on mice expressing WT-HFE (have normal iron;
able to protect cells from iron overload) should yield results indi-
cating the extent to which diet-induced changes affect iron and
cholesterol metabolism in the brain.
HOW DOES H63D-HFE AFFECT INTERACTIONS BETWEEN GLIAL AND
NEURONAL CELLS?
Experimental results indicate that H63D-HFE creates a permissive
milieu for pathogenic processes (Lee et al., 2007; Mitchell et al.,
2009a,b; Hall et al., 2010, 2011; Mairuae et al., 2010; Ali-Rahmani
et al., 2011; Liu et al., 2011). These observations raise the question
of how the effects of iron accumulation and resulting oxidative
stress, elevation of extracellular glutamate, increased secretion of
MCP-1 and 24S-HC in one cell type impacts other cells in the
brain and vice versa. The importance of this question is highlighted
by the characteristic iron-deﬁcient phenotype of macrophages in
HH patients, a puzzle that has not yet been solved. It has been
shown that although HH patients have a signiﬁcant iron overload
in their livers and other organs, their macrophages appear to be
iron-depleted (Cardoso and de Sousa, 2003). Consistent with this
observation, cell studies have shown that the normal function of
WT-HFE is not only to manage iron uptake but to prevent its
efﬂux from cells into the extracellular space (Drakesmith et al.,
2002). Because this function is impaired in H63D-HFE cells more
iron is released from macrophages (Drakesmith et al., 2002). Con-
sidering that microglia in brain function similarly to macrophages
in the circulation, expression of H63D-HFE may affect them anal-
ogously. If it does, it is likely that H63D-HFE expressing microglia
would release more iron than normal and this could affect other
cells in the CNS. Support for this is provided by results from a
number of studies that examined the effects of iron on cells in
the CNS. Zhang et al. (2007) showed that conditioned media from
iron-loaded microglia increased survival of oligodendrocytes by
delivering iron in ferritin, which could contribute to the prolif-
erative effects on oligodendrocytes. However, lipopolysaccharide
(LPS) activation of iron-loaded microglia attenuated the prolif-
erative effects on oligodendrocytes and caused them to release
inﬂammatory cytokines (Zhang et al., 2007). It has also been
shown that microglial activation and secretion of inﬂammatory
cytokines can decrease ferritin synthesis via the modulatory effects
of nitric oxide on the iron regulatory system (Chenais et al., 2002).
It is logical to argue that a decrease in ferritin along with a pre-
existing iron-overload and/or increased iron uptake would result
in more intracellular free iron that could exacerbate the oxida-
tive damage often seen in neuronal and glial cells in neurological
disorders (Rotig et al., 1997; Hirsch and Faucheux, 1998; Smith
et al., 1998). So the question is what causes microglial activation?
Iron accumulation has been shown to inﬂuence glial activation
either directly or through induction of other factors such as the
MCP-1, a chemokine (Rollins, 1997) shown to cause glial activa-
tion (Vrotsos et al., 2009) as well as induction of pro-apoptotic
genes and cell death (Zhou et al., 2006). Of particular interest is
the ﬁnding that cells expressing H63D-HFE have increased secre-
tion of MCP-1 (Mitchell et al., 2009a). Therefore, it is likely that
iron accumulation within brain cells affects microglia and this in
turn, inﬂuences the function of neurons and glia, thereby cre-
ating a vicious cycle of events that potentiate stress and damage
within the CNS. In such a scenario, endothelial cells, gatekeepers
of the BBB, could also be inﬂuenced by these changes. In fact,
experimental studies have shown that iron accumulation dam-
ages endothelial cells by induction of apoptotic pathways (Carlini
et al., 2006). Therefore, maintaining iron homeostasis is essential
for preserving endothelial function needed to maintain integrity
of the BBB. This is crucial for protecting the brain from the harm-
ful effects of chemicals that can be present in the circulation and
for maintaining a stable ﬂux of ions into the brain for proper
impulse generation and propagation by neurons. The changes in
iron and cholesterol induced by expression of H63D-HFE have
major effects on the CNS and as such their effects on neuro-glial
interactions should be further investigated. For such investiga-
tions, theH67D-HFEmousemodel could be useful sincewe found
that the animals expressed symptoms associated with human AD
(Ali-Rahmani et al., 2014a). Schematic in Figure 3 summarizes
ﬁndings from in vitro and in vivo studies with H63D variant of
HFE. The H67D-HFE mouse model could also be used to study
the effects of changes in dietary iron or cholesterol, as well as
the effects of statins and iron chelators on learning and memory.
Results of such studies could provide insights into how gene-
environmental interactions may contribute to the pathogenesis
of AD.
Because endothelial cells of brain microvasculature come in
direct contact with the red blood cells (RBCs) and exchange mate-
rial such as ions, nutrients, etc., with them, it was postulated
that characterization of RBCs may provide useful information
about the brain metabolism. The changes in the membranes of
RBCs could reﬂect alterations in the brain and such alterations
could be used as biomarkers to diagnose and monitor progres-
sion of neurological diseases. In fact, morphology of RBCs and
the protein composition of RBC membranes from RBCs iso-
lated from AD subjects were shown to be altered (Sabolovic et al.,
1997; Mohanty et al., 2010). Furthermore, oxidative stress asso-
ciated changes in the phospholipid content of RBC membranes
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isolated from RBCs from AD patients were observed (Oma et al.,
2012) and subsequently a panel of ten plasma phospholipids was
shown to predict occurrence of memory impairment in aging indi-
viduals (Mapstone et al., 2014). These ﬁndings provide support
for the hypothesis that RBC lipid dynamics could be important
determinants in neurological diseases. Further support for this
concept was provided by the observation that RBC membranes
from autistic children tended to have reduced cholesterol and
increased GM1 relative to those from healthy controls (Schen-
grund et al., 2012). Based on the ﬁnding of similar lipid changes
in neuroblastoma cells expressing H63D-HFE, a logical future
avenue of investigation would be to compare the lipid and pro-
tein composition of RBC membranes from individuals expressing
H63D-HFE with those from both healthy people and those with
neurological disorders. If indeed a biochemical proﬁle is identi-
ﬁed in RBCs from carriers of HFE variants (control, MCI, AD)
that is associated with disease pathology, it could be evaluated
for its effectiveness as a biomarker to study disease progression.
Identiﬁcation of such a biomarker would signiﬁcantly aid in
future investigations and possibly treatment. Furthermore, the
fact that decreased brain cholesterol is associated with disruption
of myelin and synapse management as well as cognitive func-
tion (Ali-Rahmani et al., 2014a), provides compelling evidence to
ascertain whether H63D-HFE is associated with increased risk of
developing autism.
POTENTIAL BIOMARKERS FOR AD PROGRESSION
It is accepted that lipids are crucial for maintenance of normal
brain function. However, it is difﬁcult to analyze its lipid con-
tent in living individuals. Due to the magnetic properties of
iron, brain iron status can be accessed, at least indirectly, by
MRI (Bartzokis et al., 1999). However, no such tool is available
to monitor the status of brain cholesterol. Owing to the high lipid
content of myelin, certain MRI techniques that measure myeli-
nation by way of quantifying white matter tracts may provide
an idea of lipid status, but no direct conclusions can be made.
Because of the difﬁculty of directly monitoring changes in the
brains of living individuals, researchers are searching for poten-
tial biomarkers that can be used to identify onset and follow
the progression, and response to treatments of neurodegenera-
tive diseases. With respect to brain cholesterol homeostasis, one
candidate proposed as an effective biomarker is 24S-HC. Almost
all 24S-HC found in plasma and CSF originates from the action
of a brain speciﬁc enzyme, CYP46A1 which catalyzes the ﬁrst step
in the clearance of cholesterol from the brain (Bjorkhem et al.,
1998). Results from a number of studies have shown an elevation
of 24S-HC either in the CSF or in the plasma of patients suf-
fering from traumatic brain injury or neurodegenerative diseases
(Bretillon et al., 2000b; Cartagena et al., 2010). More speciﬁcally, it
was found that during the early stages of AD or vascular demen-
tia (Lutjohann et al., 2000) and active periods of MS, high levels
of 24S-HC were present in either the CSF or circulation (Leoni
et al., 2002), possibly due to ongoing demyelination (Bjorkhem
and Meaney, 2004). However, in late stage AD patients’ CSF lev-
els of 24S-HC were found to be reduced (Bretillon et al., 2000a;
Leoni et al., 2002, 2006; Papassotiropoulos et al., 2002); they
were also reduced in the brains of patients who died from AD
(Heverin et al., 2004). The reduction may reﬂect the extensive
neuronal loss seen in late stages of AD. Consistent with these ﬁnd-
ings, was our observation that expression of the brain-speciﬁc
enzyme CYP46A1 is elevated in both human neuroblastoma cells
expressing H63D-HFE and in the brains of H67D-HFE mice (Ali-
Rahmani et al., 2014a). Though the amount of 24S-HC was not
measured, the observed concomitant decrease in cellular and total
brain cholesterol indicated that it is probable that the expression
of H63D/H67D would be associated with higher levels of 24S-
HC in serum or CSF or both. It would be useful to conﬁrm
this idea using the H67D mouse model. These ﬁndings could
then provide a rationale for measuring the levels of 24S-HC in
the plasma and CSF of individuals carrying H63D-HFE. If a
relationship were established between levels of plasma and CSF
24S-HC and incidence or severity of AD, it could be used as a
biomarker.
It is also possible that brain volume as determined by MRI
could be used as a biomarker for monitoring relative changes in
the impact of HFE genotype with normal aging and in disease.
This idea is based on the early reports of elevated brain iron in
the carriers of H63D (Bartzokis et al., 2010), as well as on reduced
volume of brain regions involved in memory in aged H67D-HFE
expressing mice, a ﬁnding that correlated signiﬁcantly with the
concentrations of brain cholesterol and iron, as well asmeasures of
learning andmemory (Ali-Rahmani et al., 2014a). Therefore, these
ﬁndings suggest that progression of memory decline with normal
aging and in patients diagnosed with AD could be monitored by
using volumetric MRI measurements. These tools could also be
useful for assessing the efﬁcacy of treatment. In summary, the
foregoing discussion supports the hypothesis that 24S-HC and
brain volume could be useful for monitoring disease progression
and possibly treatment efﬁcacy in carriers of H63D-HFE with a
neurodegenerative disease.
IS IT IRON ACCUMULATION OR EXPRESSION OF AN HFE VARIANT THAT
IS THE CULPRIT?
H63D and C282Y are the most common variants of HFE and
expression of either results in iron overload. Additionally, a num-
ber of other cellular processes are also altered in cells expressing
these variants. This raises the question of whether the observed
changes result from iron accumulation or occur due to a gain-of-
function of the mutation. Epidemiological studies indicate that
H63D-HFE is a risk factor for AD and C282Y-HFE for certain
cancers. Results in Table 1 summarize previous ﬁndings. The
fact that both variants of HFE, H63D, and C282Y, are associ-
ated with intracellular iron accumulation, yet result in opposing
phenotypes, H63D-HFE promoting apoptosis and C282Y-HFE
promoting cell survival, indicates that these mutations by them-
selves could be playing a role independent of their effect on cellular
iron status. Supporting this argument are the ﬁndings that their
subcellular distribution differs. Both WT- and H63D-HFE are
found in the plasma membrane, while C282Y-HFE is retained in
the ER/golgi. This striking difference is important because the sub-
cellular localization could affect protein-protein interactions and
cell signaling. Of potential importance with regard to cell signal-
ing is our observation that while WT-HFE and H63D-HFE were
localized in fractions containing lipid rafts, C282Y-HFE was not
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Table 1 | Comparison of in vivo and in vitro findings of H63D- and C282Y-HFE variants.
H63D C282Y
Iron ↑ ↑ Lee et al. (2007)
Oxidative stress ↑ ↑ Lee et al. (2007)
Cellular location Plasma membrane Endoplasmic
reticulum/golgi
Feder et al. (1997)
Cellular cholesterol ↓↓ ↑↑ Ali-Rahmani et al. (2014a,b)
GM1 ↑↑ ↓↓ Ali-Rahmani et al. (2011)
Lipid raft Yes No Ali-Rahmani et al. (2011)
Cellular phenotype ↓Cell proliferation
apoptotic
↑Cell proliferation Lee et al. (2007), Ali-Rahmani et al. (2011), Liu et al. (2011)
Disease risk AD Cancer;
protective for AD
Moalem et al. (2000), Sampietro et al. (2001), Combarros
et al. (2003), Pulliam et al. (2003), Connor and Lee (2006),
Liu et al. (2013)
(Ali-Rahmani et al., 2011). Because lipid rafts provide a platform
for a number of cell signaling pathways, an intriguing possibility
is that expression of C282Y-HFE alters at least some cell signaling
thereby disrupting normal homeostasis. Here it is important to
note that although H63D-HFE is present in lipid rafts, its interac-
tion with TfR is altered such that it loses the ability to prevent Tf
binding to TfR and iron uptake. Therefore, interactions of both
of these mutants with other proteins may be affected. Currently,
other binding partners of WT and mutant HFE proteins are not
known and should be interrogated in order to elucidate its role in
cell signaling. In response to the question of whether the variant
itself is a culprit, current evidence indicates that the variant per se
as well as the resulting iron overload contribute to the observed
effects.
Another potential area for future investigation is to identify pro-
teins that act asmolecular switches in the cell andwhose expression
and/or activity are directly regulated by cellular iron content. This
would help to dissect the molecular mechanism(s) underlying
a wide array of processes and diseases such as AD and cancer
in which iron is implicated. One possible candidate is peptidyl-
prolyl cis-trans isomerase (Pin1). It is known to play a key role
in regulation of signal transduction pathways (Wulf et al., 2005),
particularly in cell proliferation (Lu et al., 1996). Phosphorylation
of Pin1 causes it to become inactive. Pin1 modulates the folding,
activity, and stability of target proteins by causing their isomer-
ization. The ﬁndings that Pin1 is downregulated in degenerating
neurons from AD patients (Liou et al., 2003) but its expression
and activity is elevated in many cancers including those of the
breast, prostate, brain, lung, and colon (Ryo et al., 2001; Wulf
et al., 2001; Ayala et al., 2003; Bao et al., 2004), provides support
for the argument that Pin1 can serve as a molecular switch. Inter-
estingly, varying concentrations of iron were shown to alter Pin1
phosphorylation and activity in WT- and H63D-HFE cells, indi-
cating that iron can modulate Pin1 activity, but the change in
expression is HFE genotype dependent (Hall et al., 2010); present-
ing another example were HFE genotype could impact cellular
basis of disease.
THERAPEUTIC IMPLICATIONS: IS STATIN THERAPY APPROPRIATE FOR
PATIENTS WITH AD AND THE HFE-H63D GENE VARIANT?
Because AD is a multifactorial disease with evidence for the
involvement of environmental factors, multiple pathways and
geneticmutations in genes with diverse functions, it would be ben-
eﬁcial to identify subpopulations responsive to speciﬁc treatments
based on their genotype. Identiﬁcation of genetic and environ-
mental factors, knowledge about their interactions, and resulting
pathological markers should allow us to improve therapeutic out-
comes. The studies described regarding the effects of a mutation
affecting iron uptake on cholesterolmetabolism and their relation-
ship to neurodegeneration support our position that eventually
medical interventionsmust takeHFE genotype into consideration.
For example, the observation that cells carrying the H63D-HFE
allele have lower baseline levels of total cholesterol and exhibit
slower growth relative to those expressing WT-HFE (Ali-Rahmani
et al., 2014a) supports the idea that H63D-HFE positive patients
with AD will differ from those with WT-HFE in their response
to statin therapy. Our ﬁndings that treatment of H63D-HFE cells
with a statin that can cross the BBB resulted in decreased cell sur-
vival and that statin treatment of the ALS mouse model that also
carries the HFE-H63D gene variant worsens the disease (unpub-
lished data) supports this proposal. These data imply that lowering
CNS cholesterol could be deleterious to neuronal function, and
more so in the carriers of H63D-HFE. Further support for this pro-
posal is provided by a recent clinical trial that showed a reduction
in right hippocampal volume after 1 year of atorvastatin ther-
apy in AD patients (Sparks et al., 2008). Though in this study
they didn’t stratify based on HFE genotype, such an investigation
will be valuable. This ﬁnding suggests that in addition to lowering
plasma cholesterol levels inADpatients, statin treatmentmay have
reduced brain cholesterol possibly resulting in neuronal loss and
atrophy of certain brain regions. Thus, our data are suggesting that
use of statins that can cross the BBB, particularly in the presence
of HFE gene variants should be evaluated clinically.
In conclusion, the research discussed points out a connection
between iron, cholesterol, and neuronal function. This review also
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provides a synopsis of some of the many questions about the roles
that iron, cholesterol, and sphingolipids may have in the evolution
of dementing diseases in the brain and introduces a new concept,
namely that HFE gene variants dramatically inﬂuence cholesterol
metabolism.
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